BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 6887938)

  • 1. Treatment outcome of recurrent cervical cancer.
    Chung CK; Nahhas WA; Stryker JA; Mortel R
    J Surg Oncol; 1983 Sep; 24(1):5-10. PubMed ID: 6887938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage radiotherapy with or without concurrent chemotherapy for pelvic recurrence after hysterectomy alone for early-stage uterine cervical cancer.
    Kim SW; Chun M; Ryu HS; Chang SJ; Kong TW; Lee EJ; Lee YH; Oh YT
    Strahlenther Onkol; 2017 Jul; 193(7):534-542. PubMed ID: 28357468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pelvic wall recurrence of cervix carcinomas. Combined surgical-radio-chemotherapeutic procedure (CORCT)].
    Schulz-Wendtland R; Krämer S; Säbel M; Heller F; Keilholz L; Jäger W; Sauer R; Lang N; Bautz W
    Strahlenther Onkol; 1998 May; 174(5):279-83. PubMed ID: 9614958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal therapy for pelvic recurrence after radical hysterectomy for early-stage cervical cancer.
    Potter ME; Alvarez RD; Gay FL; Shingleton HM; Soong SJ; Hatch KD
    Gynecol Oncol; 1990 Apr; 37(1):74-7. PubMed ID: 2323616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Treatment of Pelvic Locoregional Recurrence of Cervical Cancer After Radical Surgery With Intensity-Modulated Radiation Therapy Compared With Conventional Radiotherapy: A Retrospective Study.
    Yin YJ; Li HQ; Sheng XG; Du XL; Wang C; Lu CH; Pan CX
    Int J Gynecol Cancer; 2015 Jul; 25(6):1058-65. PubMed ID: 25647254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience.
    Okazawa M; Mabuchi S; Isohashi F; Suzuki O; Yoshioka Y; Sasano T; Ohta Y; Kamiura S; Ogawa K; Kimura T
    Int J Gynecol Cancer; 2013 Mar; 23(3):567-75. PubMed ID: 23385284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of prognostic factors and therapeutic patterns of recurrent stage Ⅰb-Ⅱa cervical squamous carcinoma treated with radical hysterectomy].
    Ou ZJ; Zhao D; An JS; Sun CY; Huang MN; Li B; Wu LY
    Zhonghua Fu Chan Ke Za Zhi; 2019 Jun; 54(6):399-405. PubMed ID: 31262124
    [No Abstract]   [Full Text] [Related]  

  • 8. Radiation therapy of pelvic recurrence after radical hysterectomy for cervical carcinoma.
    Ijaz T; Eifel PJ; Burke T; Oswald MJ
    Gynecol Oncol; 1998 Aug; 70(2):241-6. PubMed ID: 9740698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of recurrent cervical cancer.
    Lai CH
    Chang Gung Med J; 2004 Oct; 27(10):711-7. PubMed ID: 15646293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective review of patients with stage IB2 cervical cancer treated with radical radiation versus radical surgery as a primary modality.
    Alleyne-Mike K; van Wijk L; Hunter A
    Int J Gynecol Cancer; 2013 Sep; 23(7):1287-94. PubMed ID: 23863456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. State-of-the-Art Treatment and Novel Agents in Local and Distant Recurrences of Cervical Cancer.
    Tempfer CB; Beckmann MW
    Oncol Res Treat; 2016; 39(9):525-33. PubMed ID: 27614445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indications for primary and secondary exenterations in patients with cervical cancer.
    Marnitz S; Köhler C; Müller M; Behrens K; Hasenbein K; Schneider A
    Gynecol Oncol; 2006 Dec; 103(3):1023-30. PubMed ID: 16890276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival after curative pelvic exenteration for primary or recurrent cervical cancer: a retrospective multicentric study of 167 patients.
    Chiantera V; Rossi M; De Iaco P; Koehler C; Marnitz S; Ferrandina G; Legge F; Parazzini F; Scambia G; Schneider A; Vercellino GF
    Int J Gynecol Cancer; 2014 Jun; 24(5):916-22. PubMed ID: 24442006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Neoadjuvant Chemotherapy Plus Radical Surgery as Front Line Treatment Strategy in Patients Affected by FIGO Stage III Cervical Cancer.
    Di Donato V; Schiavi MC; Ruscito I; Visentin VS; Palaia I; Marchetti C; Fischetti M; Monti M; Muzii L; Benedetti Panici P
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):841-849. PubMed ID: 27678502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study of adjuvant therapy in patients with cervical cancer at high risk of recurrence after radical hysterectomy and pelvic lymphadenectomy.
    Wertheim MS; Hakes TB; Daghestani AN; Nori D; Smith DH; Lewis JL
    J Clin Oncol; 1985 Jul; 3(7):912-6. PubMed ID: 2410573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical analysis of 32 cases with neuroendocrine carcinoma of the uterine cervix in early-stage disease].
    Wang Z; Wu L; Yao H; Sun Y; Li X; Li B; Zhang R; Ma S; Huang M
    Zhonghua Fu Chan Ke Za Zhi; 2015 Mar; 50(3):198-203. PubMed ID: 26268410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy followed by radical surgery and radiotherapy vs. pelvic irradiation in patients with cervical cancer FIGO stage IIB - IVA.
    Kornovski Y; Gorchev G
    J BUON; 2006; 11(3):291-7. PubMed ID: 17309152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant Small Pelvic Radiotherapy in Patients with Cervical Cancer Having Intermediate Risk Factors Only - Is It Sufficient?
    Yuce Sari S; Guler OC; Gultekin M; Onal HC; Yildiz F
    Oncol Res Treat; 2017; 40(9):523-527. PubMed ID: 28848218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors in FIGO stage IB cervical cancer without lymph node metastasis and the role of adjuvant radiotherapy after radical hysterectomy.
    Ayhan A; Al RA; Baykal C; Demirtas E; Ayhan A; Yüce K
    Int J Gynecol Cancer; 2004; 14(2):286-92. PubMed ID: 15086728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early stage cervical cancer: Brachytherapy followed by type a hysterectomy versus type B radical hysterectomy alone, a retrospective evaluation.
    Lacorre A; Merlot B; Garabedian C; Narducci F; Chereau E; Resbeut M; Minsat M; Leblanc E; Houvenaeghel G; Lambaudie E
    Eur J Surg Oncol; 2016 Mar; 42(3):376-82. PubMed ID: 26725307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.